Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2014 December;56(4) > Panminerva Medica 2014 December;56(4):263-72

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

PANMINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6


eTOC

 

  MENOPAUSE IN 2014


Panminerva Medica 2014 December;56(4):263-72

language: English

Hormone replacement therapy: consensus and controversies

Shoupe D.

Division of Reproductive Endocrinology and Infertility, Keck School of Medicine, University of Southern California, Los Angeles, CA, US


PDF  


While the use of menopausal hormone therapy [MHT] when initiated in women younger than 60 years is generally considered to have a good safety profile and to be associated with important treatment and prevention benefits, the length of therapy and the long-term risk benefit profile remains highly controversial.

top of page

Publication History

Cite this article as

Corresponding author e-mail

shoupe@usc.edu